Abbott to buy Cologuard test maker Exact Sciences for $21 billion
MLex Summary: Biotechnology corporation Abbott intends to pay $105 per share to acquire cancer diagnostics firm Exact Sciences, the creator of the Cologuard screening test for colorectal cancers and the Cancerguard...To view the full article, register now.
Already a subscriber? Click here to view full article